Showing results (21-30 of 31) with videos related to
Sort By:
Pageof 4
Journal for Immunotherapy of Cancer|July 15, 2025
Napsin A-specific T-cell clonotypes are associated with improved clinical outcomes in patients receiving checkpoint immunotherapy for metastatic non-small cell lung cancerNatalie J Miller, Christina Baik, Joel W Neal, et al.Cancer Discovery|September 22, 2021
Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung CancerPasi A Jänne, Christina Baik, Wu-Chou Su, et al.JTO Clinical and Research Reports|June 29, 2026
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein Overexpressing, Nonsquamous, EGFR Wild-type Advanced NSCLC: Updated Analysis of the LUMINOSITY TrialNicolas Girard, Jonathan Goldman, Shun Lu, et al.International Journal of Radiation Oncology, Biology, Physics|November 23, 2019
A Pilot Study of Atezolizumab Plus Hypofractionated Image Guided Radiation Therapy for the Treatment of Advanced Non-Small Cell Lung CancerAngel Qin, Ramesh Rengan, Sylvia Lee, et al.JTO Clinical and Research Reports|April 27, 2026
Durvalumab Plus Chemotherapy in Patients With EGFR-Mutated Advanced NSCLC Whose Disease Progressed on First-Line Osimertinib: ORCHARDByoung Chul Cho, Makoto Nishio, Myung-Ju Ahn, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2026
Osimertinib Plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARDSarah B Goldberg, Myung-Ju Ahn, Christina Baik, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 28, 2023
Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLCKaiwen Wang, Robyn Du, Nathaniel J Myall, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 8, 2024
A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve EGFR-Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial)Xiuning Le, Jyoti D Patel, Elaine Shum, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2024
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous EGFR-Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY TrialD Ross Camidge, Jair Bar, Hidehito Horinouchi, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 27, 2019
Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker AnalysesTaofeek K Owonikoko, Huifeng Niu, Kristiaan Nackaerts, et al.Pageof 4